Related Experiment Video
Updated: Mar 2, 2026
12:36
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
17.8K
Targeting the gut-liver axis in liver disease
Reiner Wiest1, Agustin Albillos2, Michael Trauner3
1Gastroenterology, University Hospital, 3010 Bern, Switzerland.
Journal of Hepatology
|May 21, 2017
Summary
The gut-liver axis plays a key role in liver disease. Emerging therapies targeting this connection show promise for future liver treatments.
Area of Science:
- Gastroenterology and Hepatology
- Microbiome Research
- Immunology
Background:
- The gut-liver axis is a critical factor in liver disease development.
- Clinical research is increasingly focused on understanding and intervening in this axis.
- Dysregulation of the gut-liver axis contributes to various liver pathologies.
Purpose of the Study:
- To review current therapeutic and preventative strategies targeting the gut-liver axis.
- To highlight the expanding potential of interventions in liver disease treatment.
- To underscore the future prospects of clinical trials informed by gut-liver axis research.
Main Methods:
- Literature review of recent studies on gut-liver axis interventions.
- Analysis of clinical trial outcomes for novel therapeutic strategies.
- Synthesis of current knowledge on the gut-liver axis in liver disease.
Main Results:
- Recent therapeutic and preventative strategies targeting the gut-liver axis have shown promising results.
- The range of available treatments for liver diseases involving the gut-liver axis is expanding.
- Clinical trials demonstrate the efficacy of interventions modulating the gut-liver axis.
Conclusions:
- Targeting the gut-liver axis offers a promising avenue for managing liver diseases.
- Continued research and clinical trials will expand the therapeutic armamentarium for liver conditions.
- The future of liver treatment is significantly influenced by advancements in understanding the gut-liver axis.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
01:26Diseases of the Liver and Gallbladder
2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
01:30Liver Physiology
4.0K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.0K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
268
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
268